CapForce Inc. · OTC:CFOR
CapForce — Opgen — Investor Presentation (April 2020)
27 slides from CapForce's investor presentation, Apr 14, 2020
Slide 1: OpGen Corporate Overview April 2020
OpGen Corporate Overview April 2020
Slide 2: Forward Looking Statements Disclaimer
FORWARD LOOKING STATEMENTS DISCLAIMER 2 ©2020 OpGen, Inc. This presentation contains forward - looking statements that are subject to many risks and uncertainties. These statements, among other things, relate to our business strategy, goals and expectations concerning our products, future operations
Slide 3: OpGen and Curetis Complete Business Combination
OPGEN AND CURETIS COMPLETE BUSINESS COMBINATION 3 ©2020 OpGen, Inc.
Slide 4: OpGen and Its Group Companies: Striving to Innovate Molecular Microbiology
OPGEN AND ITS GROUP COMPANIES: STRIVING TO INNOVATE MOLECULAR MICROBIOLOGY 4 Fast Comprehensive AI - Powered AMR Prediction & Bioinformatics Rapid Pathogen Detection For Life Threatening Infections Broad Pathogen & Antimicrobial Resistance (AMR) Marker Coverage Smart Easy Sample - To - Answer Platfo
Slide 5: Combined Company's Portfolio: Synergistic Products & Capabilities
COMBINED COMPANY’S PORTFOLIO: SYNERGISTIC PRODUCTS & CAPABILITIES Unyvero Platform & Syndromic Tests Acuitas Tests & Acuitas Lighthouse Direct sales in U.S., European and China distribution with partners; 18 distributors covering 43 countries; CoV - 2 test kit distribution in EMEA Unyvero FDA - clea
Slide 6: Strategic Rationale and Benefits
STRATEGIC RATIONALE AND BENEFITS Well positioned to capitalize on global opportunities in infectious disease and rapid AMR detection Proprietary molecular diagnostic tests and platforms Premier AI - powered bioinformatics solutions for multi - drug resistance diagnostics Global commercial channel ca
Slide 7: U.S. and European Markets With ~10 Million Hospitalized Patients Annually
U.S. And European Markets With ~10 Million Hospitalized Patients Annually Addressed Through Hospital - Focused Sales Channels COMBINED COMPANY TO ADDRESS UNMET CLINICAL NEEDS AND LARGE AVAILABLE MARKET OPPORTUNITIES The current Unyvero portfolio and pipeline of cartridges according to management est
Slide 8: Strategic Rationale and Benefits
STRATEGIC RATIONALE AND BENEFITS ©2020 OpGen, Inc. Well positioned to capitalize on global opportunities in infectious disease and rapid AMR detection Proprietary molecular diagnostic tests and platforms Premier AI - powered bioinformatics solutions for multi - drug resistance diagnostics Global com
Slide 9: Innovating Molecular Microbiology Through Proprietary Platforms And Content
Innovating Molecular Microbiology Through Proprietary Platforms And Content SAMPLE - TO - ANSWER HIGH - THROUGHPUT TESTING CAPABILITIES * Unyvero A30 RQ Analyzer in development, latest design concept; final product may differ Striving for Molecular Microbiology Innovation MDx Platforms MDx Content L
Slide 10: Broad Unyvero Cartridge Portfolio
BROAD UNYVERO CARTRIDGE PORTFOLIO 10 HPN / LRT BAL* Hospitalized Pneumonia / Lower Respiratory Tract Infections ITI Implant & Tissue Infection IAI Intra - Abdominal Infection BCU Blood Culture UTI Urinary Tract Infection ©2020 OpGen, Inc. * Unyvero LRT / LRT BAL are FDA cleared – all other products
Slide 11: Unyvero Cartridge Indications, Targets and Clearance Status
Cartridge Indication area Number of targets Sample types Clearance status HPN** Severe cases of Pneumonia 48 targets****, pathogens (29) and antibiotic resistance markers (19) Sputum, broncho - alveolar lavage, tracheal aspirate CE - IVD marked Singapore (HAS) Thailand Malaysia LRT & LRT BAL Lower R
Slide 12: Current U.S. Product Offerings: Unyvero LRT & LRT BAL
CURRENT U.S. PRODUCT OFFERINGS: UNYVERO LRT & LRT BAL 12 Providing Clear Direction • FDA - cleared, sample - to - answer, in less than 5 hours with just about 2 min hands - on time • Direct from native specimen, FDA - cleared for bronchoalveolar lavage fluids and tracheal aspirates • Multiplex PCR w
Slide 13: Current U.S. Product Offerings: Acuitas AMR Gene Panel
CURRENT U.S. PRODUCT OFFERINGS: ACUITAS AMR GENE PANEL* 13 IDENTIFIES Up to 47 Resistance Genes, Spanning 9 Antibiotic Classes TESTS Directly from Urine (in clinical trials) or Isolated Colonies (FDA Clearance Decision Pending), Sample - to - Answer Multiplex PCR from Bacterial Isolates (or Native U
Slide 14: Unyvero A30 RQ Rapid Sample-to-Answer Testing Platform in Development
UNYVERO A30 RQ RAPID SAMPLE - TO - ANSWER TESTING PLATFORM IN DEVELOPMENT 14 ©2020 OpGen, Inc. Key Design Features • Fully integrated, closed, sample - to - answer MDx platform • Universal real - time PCR technology for low - to mid - plex testing • Flexible cartridge fluidics for numerous chemistri
Slide 15: Strategic Rationale and Benefits
STRATEGIC RATIONALE AND BENEFITS ©2020 OpGen, Inc. Well positioned to capitalize on global opportunities in infectious disease and rapid AMR detection Proprietary molecular diagnostic tests and platforms Premier AI - powered bioinformatics solutions for multi - drug resistance diagnostics Global com
Slide 16: Ares Genetics & ARESdb
16 ARES GENETICS & ARESdb * ©2020 OpGen, Inc. Bioinformatics Powerhouse With Industry - Leading Proprietary AI - Powered AMR Knowledgebase for Molecular Microbiology Global ARESdb Database • Unique Knowledgebase on Antibiotic Resistance Markers building on SIEMENS Microbiology Strain Collection • De
Slide 17: Acuitas Lighthouse: Diagnostics Data Management Platform
Cloud - based bioinformatics platform powers our ability to trace AMR in real - time with the potential to change the landscape of clinical infectious disease management and improve outcomes for patients ACUITAS LIGHTHOUSE®: DIAGNOSTICS DATA MANAGEMENT PLATFORM FOR ANTIBIOTIC RESISTANT PATHOGENS * R
Slide 18: Strategic Rationale and Benefits
STRATEGIC RATIONALE AND BENEFITS Well positioned to capitalize on global opportunities in infectious disease and rapid AMR detection Proprietary molecular diagnostic tests and platforms Premier AI - powered bioinformatics solutions for multi - drug resistance diagnostics Global commercial channel ca
Slide 19: Leveraging Synergies From Our Combined Commercial Team Structures
Leveraging Synergies From Our Now Combined Commercial Team Structures DUAL COMMERCIAL MODEL Expanding global c ommercial r each though direct sales in U.S. and via global distributors > Direct sales in the U.S. > European distribution through Menarini Diagnostics > China distribution through Beijing
Slide 20: Pan European Distribution via Menarini
Currently 11 EU Countries – Option To Expand Relationship To Further EMEA Markets And Additional Product Lines PAN EUROPEAN DISTRIBUTION VIA MENARINI Menarini Diagnostics & Curetis Collaboration ( since Q1 - 2019) > Covers entire Unyvero A50 product line > Initial countries: BE, CH, DE, ES, FR, IT,
Slide 21: Strategic Rationale and Benefits
STRATEGIC RATIONALE AND BENEFITS ©2020 OpGen, Inc. Well positioned to capitalize on global opportunities in infectious disease and rapid AMR detection Proprietary molecular diagnostic tests and platforms Premier AI - powered bioinformatics solutions for multi - drug resistance diagnostics Global com
Slide 22: Financial Considerations
FINANCIAL CONSIDERATIONS • Proforma Revenue : • FY2018 revenues of $4.5 • FY2019 revenues of $6.0 million • No revenue guidance for 2020 at this time due to COVID - 19 situation • Cash Position : • March 31, 2020 - $11.5 million • Cash raised via ATM and Warrant exercises YTD 2020 - $14.3 million •
Slide 23: Financial Considerations: Other Key Items
FINANCIAL CONSIDERATIONS • Other Key Items • 15,000 sq. ft. FDA registered R&D/ Manufacturing facility in Maryland • 16,000 sq. ft. FDA registered Manufacturing facility in Germany • 15 Acuitas AMR Gene panel system placements • ~ 170 Unyvero Analyzer placements globally (of which ~35 in the U.S.) •
Slide 24: New OpGen Inc. Executive Leadership Team and Board
NEW OPGEN INC. EXECUTIVE LEADERSHIP TEAM AND BOARD Combined Team Has Decades Of Experience In Precision Medicine, Molecular Diagnostics And Capital Markets Chief Executive Officer: Oliver Schacht, Ph.D. Chief Financial Officer: Timothy (Tim) C. Dec Chief Operating Officer: Johannes (Jan) Bacher Boar
Slide 25: Upcoming Milestones, Newsflow & Catalysts
UPCOMING MILESTONES, NEWSFLOW & CATALYSTS Unyvero & Acuitas ® Rapid Molecular Tests • FDA clearance decision Acuitas ® AMR Gene Panel (isolates) • USA commercial updates on Unyvero LRT / LRT BAL adoption for bacterial co - infections in COVID - 19 ICU patients • Portfolio news on various SARS - CoV
Slide 26: Contact Info
CONTACT INFO 26 OpGen Inc. (Global HQ) 708 Quince Orchard Road Gaithersburg, MD 20878 USA P +1 301.869.9683 [email protected] Curetis GmbH Max - Eyth - Str. 42 71088 Holzgerlingen Germany P +49 (0)7031 49195 - 10 [email protected] ©2020 OpGen, Inc. Ares Genetics GmbH Karl - Farkas - Gass
Slide 27: Thank You!
Thank You ! 27 ©2020 OpGen, Inc .